|
JENEX AGREES TO U.S. MARKET TEST FOR THERAPIK
May 26, 2005
Burlington, Ontario
THE JENEX CORPORATION (“Jenex”) (TSX Venture Exchange – JEN) is pleased to report they have received a $70,000 USD order for Therapik® from a significant marketing company in the United States. This is the largest single order for the Therapik® product to date. This is a single order, non-exclusive arrangement, for the marketing company to test market Therapik® and determine their interest in pursuing an exclusive marketing and sales arrangement for Therapik® in the US market. Michael Jenkins, President & CEO of Jenex said “We are optimistic about this test market with Therapik® and the licensing potential in the United States that could deliver significant sales and revenue opportunities for Jenex.”
The Therapik® product relieves the pain, itch and inflammation associated with stings and bites from insects such as wasps, bees, and hornets, and sea creatures such as jellyfish, weaver fish and scorpion fish. Therapik® has been approved as a Class II medical device in Canada and the United States.
About The Jenex Corporation
Headquartered in Burlington, Ontario, the Corporation owns a patented Thermal Therapy Technology. Patents in the United States, Canada, Australia, and Europe protect the technology. The first device developed from this technology is the Therapik® product, for insect stings and bites. Therapik® has been approved as a Class II medical device in Canada and the United States. In 2004, Jenex signed an exclusive multi-year licensing agreement for Therapik® for 22 Asian countries. Licensing partners are being pursued for other world markets. The second device, interceptCS™ is the first product proven and approved to prevent cold sores. Jenex has been approved to market interceptCS in Canada with its approved claim, "For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks". The Corporation is preparing for the launch of interceptCS in the Canadian market in 2005. More information about the Corporation can be found at www.JenexCorp.com .
Enquiries:
Michael A. Jenkins, President
The Jenex Corporation
940 Sheldon Court, Suite 207
Burlington, Ontario
L7L 5K6
Telephone: (905) 632-3830
Facsimile: (905) 632-3774
Email: jenex@jenexcorp.com
The TSX Venture Exchange has not reviewed and does not accept responsibility for the accuracy or the contents of this press release. Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events.
|
